| Name | Title | Contact Details |
|---|
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Rothenberger USA is a Rockford, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Regional Consultants Hematology and Onocology is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NexMed, Inc. (NASDAQ: NEXM), due to its recent acquisition of Bio-Quant, Inc., a revenue-generating specialty contract research organization performing in vitro and in vivo pharmacology services, is now the largest specialty CRO based in San Diego, CA.
Mount Nittany Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in State College, PA. To find more information about Mount Nittany Medical Center, please visit www.mountnittany.org